2013-18: Somatostatin analogues for the treatment of chronic macular edema in retinal disease
Macular edema (ME) is one of the most frequent causes of central vision loss in retinal diseases. Chronic ME is often difficult to treat. Somatostatin receptors are found in almost all ocular structures including the retinal pigment epithelium (RPE), and activation of these receptors in the RPE is believed to support the apical-basal directed fluid transport. It is therefore thought that somatostatin analogues can be used as a therapeutic agent in chronic, refractory ME. This retrospective case series will be analysed in order to study the efficacy and safety of somatostatine analogs, Octreotide long acting repeatable (LAR) or Lanreotide, in chronic ME related to various retinal diseases.